Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. Topical / intralesional corticosteroids and topical or contact immunotherapy are mainstay treatments for AA. In mid 2022, the first therapy gained FDA approval for the treatment of AA: Eli Lilly’s JAK inhibitor Olumiant (baricitinib); two other JAK inhibitors—Pfizer’s Xeljanz (tofacitinib) and Incyte’s Jakafi (ruxolitinib [oral])—are also prescribed off-label for AA, albeit infrequently. As the U.S. AA current treatment landscape continues to evolve, this report offers insights, informed by patient-level claims data, into prescribing trends in AA to help current and future players better understand existing treatment practices in AA and to define the market niche for emerging products.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key drugs: Contact allergens, corticosteroids, cyclosporine A, finasteride, Jakafi, methotrexate, Olumiant, pimecrolimus, retinoids, tacrolimus (topical), Xeljanz
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.